Amphastar Pharmaceuticals, Inc. AMPH R2K
Company Overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Why Investors Should Care
Revenue has grown at a 13.0% CAGR over the past five years.
Trades at a P/E of 11.3, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $719.89M (-1.7% YoY); net profit $98.09M.
- Trailing 12 Months Year-on-year growth — revenue +0.4%, earnings -72.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.0%, profit CAGR 2.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.99% |
| 1 Year: | 0.40% |
Compounded Profit Growth
| 5 Years: | 2.39% |
| 1 Year: | -72.50% |
Stock Price Performance
| 1 Year: | -14.31% |
| 6 Months: | -32.19% |
| 3 Months: | -11.94% |
| 1 Month: | -8.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.17 · Neutral
P/E of 11.33 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 39.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMPH Amphastar Pharmaceuticals, Inc. R2K | 18.81 | 11.33 | $829.39M | 0.00% | 10.14% | 10.39% | 12.99% | 2.39% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 56.67M | 65.19M | 57.92M | 60.40M | 58.39M | 71.04M | 75.54M | 89.69M | 79.79M | 79.05M | 80.14M | 83.38M | 84.69M | 85.81M | 83.43M | 103.02M | 101.66M | 112.20M | 120.37M | 123.47M | 120.13M | 140.02M | 145.71M | 180.56M | 171.84M | 182.39M | 191.21M | - | 170.53M | 174.41M | 191.84M | 183.10M | 171.17M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.28M | 87.92M | 93.19M | 97.44M | 100.85M |
| Gross Profit | 13.32M | 17.58M | 33.17M | 24.90M | 31.71M | 27.61M | 19.96M | 22.81M | 26.66M | 20.55M | 20.49M | 16.97M | 26.06M | 29.26M | 34.69M | 30.90M | 32.39M | 35.25M | 33.38M | 36.82M | 33.18M | 36.51M | 44.95M | 47.38M | 51.18M | 55.83M | 63.36M | 58.51M | 73.84M | 72.74M | 108.40M | 90.10M | 95.17M | 101.94M | - | 85.25M | 86.49M | 98.65M | 85.67M | 70.32M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.96M | 44.31M | 73.33M | 50.06M | 56.69M |
| Operating Income | -10.26M | -3.75M | - | 4.08M | 10.33M | 5.80M | - | 1.40M | 2.19M | -2.94M | - | -9.78M | -2.94M | 2.55M | - | -3.17M | 973.00K | 2.40M | - | 7.48M | -2.92M | 3.52M | 10.31M | 10.56M | 24.77M | 21.61M | 24.82M | 23.23M | 33.43M | 36.90M | 72.68M | 48.01M | 55.22M | 57.05M | - | 37.29M | 42.18M | 25.32M | 35.61M | 13.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.35M | 61.85M | 43.56M | 54.53M | 33.10M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.29M | 6.28M | 6.28M | 6.63M | 6.55M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.86M | 39.34M | 21.51M | 31.91M | 10.05M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.58M | 8.30M | 4.16M | 7.49M | 3.63M |
| Net Income | -6.65M | -3.01M | 7.53M | 2.49M | 6.89M | 3.89M | -2.74M | 893.00K | 1.97M | 99.00K | 1.47M | -7.14M | -2.85M | 2.39M | 1.87M | 868.00K | 47.79M | 1.31M | -1.03M | 3.95M | -192.00K | 3.92M | 5.04M | 7.77M | 29.55M | 24.25M | 17.35M | 15.87M | 26.03M | 26.12M | 49.22M | 43.18M | 37.95M | 40.43M | - | 25.29M | 31.03M | 17.35M | 24.43M | 6.42M |
| Diluted EPS | -0.15 | -0.07 | 0.16 | 0.05 | 0.15 | 0.08 | -0.06 | 0.02 | 0.04 | 0.00 | 0.02 | -0.15 | -0.06 | 0.05 | 0.04 | 0.02 | 0.96 | 0.03 | -0.02 | 0.08 | 0.00 | 0.08 | 0.10 | 0.16 | 0.59 | 0.47 | 0.33 | 0.30 | 0.50 | 0.49 | 0.91 | 0.81 | 0.73 | 0.78 | - | 0.51 | 0.64 | 0.37 | 0.51 | 0.14 |
| R&D Expense | 10.73M | 11.12M | - | 8.61M | 10.59M | 9.72M | - | 11.25M | 10.73M | 10.07M | - | 14.03M | 15.46M | 11.34M | - | 14.61M | 16.00M | 18.61M | - | 15.30M | 16.15M | 17.64M | 14.77M | 18.12M | 10.76M | 16.22M | 22.80M | 18.51M | 19.82M | 16.84M | 16.66M | 17.04M | 17.65M | 21.08M | - | 20.10M | 20.08M | 22.35M | - | 26.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 204.32M | 229.68M | 210.46M | 251.52M | 255.16M | 240.18M | 294.67M | 322.36M | 349.85M | - | 498.99M | 644.39M | 731.97M | 719.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 250.13M | 293.27M | 358.11M | 363.83M |
| Gross Profit | 90.30M | 86.96M | 51.26M | 77.35M | 104.20M | 90.51M | 106.98M | 131.92M | 143.34M | - | 248.86M | 351.12M | 373.86M | 356.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 141.36M | 154.13M | 168.44M | 215.65M |
| Operating Income | 25.40M | 17.49M | -17.98M | -6.90M | 15.38M | -1.27M | -8.62M | -39.00K | 10.95M | - | 107.50M | 196.99M | 205.42M | 140.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 146.16M | 240.29M | 277.31M | 212.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.85M | 27.16M | 30.34M | 25.48M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 116.04M | 171.36M | 189.76M | 123.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 23.48M | 31.83M | 29.67M | 25.53M |
| Net Income | 18.09M | 11.86M | -10.70M | -2.79M | 9.82M | 3.65M | -5.74M | 48.94M | 1.40M | - | 91.39M | 137.54M | 159.52M | 98.09M |
| Diluted EPS | 0.46 | 0.31 | -0.25 | -0.06 | 0.21 | 0.08 | -0.12 | 0.98 | 0.03 | - | 1.74 | 2.60 | 3.06 | 2.03 |
| R&D Expense | 31.16M | 33.02M | 28.87M | 37.27M | 41.52M | 43.50M | 57.56M | 68.85M | 67.23M | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 338.75M | 389.37M | 390.14M | 427.74M | 451.07M | 513.56M | 586.97M | 631.24M | - | 741.99M | 1.51B | 1.58B | 1.63B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 378.32M | 489.60M | 534.07M | 636.02M |
| Cash & Equivalents | 53.74M | 50.21M | 53.59M | 67.83M | 66.07M | 72.35M | 65.59M | 86.34M | 73.69M | 92.64M | - | 156.10M | 144.30M | 151.61M | 170.18M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 103.58M | 105.83M | 153.74M | 176.89M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 88.80M | 114.94M | 136.29M | 143.56M |
| Total Liabilities | - | - | 87.20M | 107.51M | 94.63M | 98.48M | 117.34M | 149.20M | 159.44M | 182.51M | - | 213.33M | 873.49M | 845.17M | 840.49M |
| Current Liabilities | - | - | 65.40M | 62.59M | 59.95M | 60.62M | 67.19M | 106.83M | 90.01M | 112.20M | - | 94.86M | 225.41M | 173.76M | 158.16M |
| Long Term Debt | - | - | - | 42.68M | 40.30M | 36.03M | 45.72M | 49.10M | 46.32M | 45.92M | - | 72.84M | 589.58M | 601.63M | 608.75M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 102.58M | 623.64M | 650.55M | 656.00M |
| Total Equity | 208.52M | 233.44M | 251.54M | 281.86M | 295.51M | 329.25M | 333.74M | 332.44M | 381.37M | 402.31M | - | 528.66M | 639.42M | 732.30M | 788.80M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 58.11M | 59.39M | 60.85M | 61.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 10.68M | 38.56M | 39.21M | 38.19M | 41.76M | 57.27M | - | 89.18M | 183.50M | 213.39M | 156.12M |
| Investing Cash Flow | - | - | - | -16.93M | -39.50M | -36.89M | -42.18M | -50.53M | -36.41M | - | -32.78M | -649.12M | -124.93M | -70.33M |
| Financing Cash Flow | - | - | - | 2.24M | 7.14M | -7.72M | 25.01M | -3.78M | -2.25M | - | -26.44M | 454.09M | -80.95M | -67.42M |
| Capital Expenditure | -23.13M | -17.64M | -20.50M | -16.00M | -21.38M | -35.10M | -46.81M | -41.55M | -33.85M | - | -24.03M | -38.17M | -41.04M | -37.13M |
| Free Cash Flow | - | - | - | -5.32M | 17.18M | 4.11M | -8.62M | 207.00K | 23.41M | - | 65.15M | 145.34M | 172.34M | 118.98M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 29.96M | -11.52M | 7.50M | 18.36M |
| Share Buybacks | 811.00K | 199.00K | 345.00K | 9.87M | 9.91M | 30.75M | 25.05M | 22.29M | 24.43M | 28.87M | 39.91M | 58.14M | 85.46M | 75.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 44.2% | 37.9% | 24.4% | 30.8% | 40.8% | 37.7% | 36.3% | 40.9% | 41.0% | - | 49.9% | 54.5% | 51.1% | 49.5% |
| Operating Margin % | 12.4% | 7.6% | -8.5% | -2.7% | 6.0% | -0.5% | -2.9% | -0.0% | 3.1% | - | 21.5% | 30.6% | 28.1% | 19.5% |
| Net Margin % | 8.9% | 5.2% | -5.1% | -1.1% | 3.8% | 1.5% | -1.9% | 15.2% | 0.4% | - | 18.3% | 21.3% | 21.8% | 13.6% |
| ROE % | 7.8% | 4.7% | -3.8% | -0.9% | 3.0% | 1.1% | -1.7% | 12.8% | 0.3% | - | 17.3% | 21.5% | 21.8% | 12.4% |
| ROCE % | - | 6.4% | -5.5% | -2.1% | 4.2% | -0.3% | -2.1% | -0.0% | 2.1% | - | 16.6% | 15.3% | 14.6% | 9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.30% | 5.42M | $104.14M |
| 2 | Dimensional Fund Advisors LP | 4.60% | 2.03M | $38.96M |
| 3 | State Street Corporation | 3.65% | 1.61M | $30.88M |
| 4 | Vanguard Capital Management LLC | 3.50% | 1.54M | $29.65M |
| 5 | TD Asset Management, Inc | 3.49% | 1.54M | $29.60M |
| 6 | Fuller & Thaler Asset Management Inc. | 3.16% | 1.40M | $26.80M |
| 7 | Marshall Wace LLP | 2.33% | 1.03M | $19.70M |
| 8 | American Century Companies Inc | 2.31% | 1.02M | $19.55M |
| 9 | Geode Capital Management, LLC | 2.21% | 976.65K | $18.76M |
| 10 | Boston Trust Walden Corporation | 2.14% | 944.79K | $18.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMPH
1 of Wall Street’s Favorite Stocks to Research Further and 2 Facing Challenges
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about comp…
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched va…
New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six m…
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Amphastar Pharmaceuticals (NASDAQ:AMPH) is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors…
AMPH — Frequently Asked Questions
What is the current share price of Amphastar Pharmaceuticals, Inc. (AMPH)?
As of 2026-07-14 21:23 PDT, Amphastar Pharmaceuticals, Inc. (AMPH) trades at $18.81 on NasdaqGS. Its 52-week range is $16.87 to $30.81.
What is the market capitalisation of AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) has a market capitalisation of $829.39M on NasdaqGS.
What is the P/E ratio of AMPH?
AMPH trades at a trailing price-to-earnings (P/E) ratio of 11.33. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.16.
What is the return on equity (ROE) of AMPH?
AMPH has a return on equity (ROE) of 10.39%. Its return on capital employed (ROCE) is 10.14%.
Is AMPH a good stock to buy?
This page provides a data-driven analysis of Amphastar Pharmaceuticals, Inc. (AMPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.